Abstract
Background: Over the past three decades, NMDA-receptor antagonists have been shown to be efficient drugs for treating pain, particularly pain resistant to conventional analgesics. Emphasis will be on the old-new drugs, ketamine and magnesium, and their combination as a novel approach for treating chronic pain.
Methods: The MEDLINE database was searched via PubMed for articles that were published up to March 1, 2020, with the keywords ‘ketamine’, ‘magnesium’, and ‘pain’ (in the title/abstract).
Results: Studies in animals, as well as humans, have shown that interactions of ketamine and magnesium can be additive, antagonistic, and synergistic. These discrepancies might be due to differences in magnesium and ketamine dosage, administration times, and the chronological order of drug administration. Different kinds of pain can also be the source of divergent results.
Conclusion: This review explains why studies performed with a combination of ketamine and magnesium have given inconsistent results. Because of the lack of efficacy of drugs available for pain, ketamine and magnesium in combination provide a novel therapeutic approach that needs to be standardized with a suitable dosing regimen, including the chronological order of drug administration.
Keywords: NMDA antagonist, pain, ketamine, magnesium, interaction, animals, humans.
CNS & Neurological Disorders - Drug Targets
Title:Interactions between Ketamine and Magnesium for the Treatment of Pain: Current State of the Art
Volume: 20 Issue: 5
Author(s): Katarina S. Vujović*, Sonja Vučković, Radan Stojanović, Nevena Divac, Branislava Medić, Aleksandar Vujović, Dragana Srebro and Milica Prostran
Affiliation:
- Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade,Serbia
Keywords: NMDA antagonist, pain, ketamine, magnesium, interaction, animals, humans.
Abstract:
Background: Over the past three decades, NMDA-receptor antagonists have been shown to be efficient drugs for treating pain, particularly pain resistant to conventional analgesics. Emphasis will be on the old-new drugs, ketamine and magnesium, and their combination as a novel approach for treating chronic pain.
Methods: The MEDLINE database was searched via PubMed for articles that were published up to March 1, 2020, with the keywords ‘ketamine’, ‘magnesium’, and ‘pain’ (in the title/abstract).
Results: Studies in animals, as well as humans, have shown that interactions of ketamine and magnesium can be additive, antagonistic, and synergistic. These discrepancies might be due to differences in magnesium and ketamine dosage, administration times, and the chronological order of drug administration. Different kinds of pain can also be the source of divergent results.
Conclusion: This review explains why studies performed with a combination of ketamine and magnesium have given inconsistent results. Because of the lack of efficacy of drugs available for pain, ketamine and magnesium in combination provide a novel therapeutic approach that needs to be standardized with a suitable dosing regimen, including the chronological order of drug administration.
Export Options
About this article
Cite this article as:
Vujović S. Katarina *, Vučković Sonja , Stojanović Radan , Divac Nevena , Medić Branislava , Vujović Aleksandar , Srebro Dragana and Prostran Milica , Interactions between Ketamine and Magnesium for the Treatment of Pain: Current State of the Art, CNS & Neurological Disorders - Drug Targets 2021; 20 (5) . https://dx.doi.org/10.2174/1871527320666210121144216
DOI https://dx.doi.org/10.2174/1871527320666210121144216 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic:Ion Channels as a Target for Drug Design (Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design Ester Prodrugs of Ketoprofen: Synthesis, In Vitro Stability, In Vivo Biological Evaluation and In Silico Comparative Docking Studies Against COX-1 and COX-2
Current Drug Discovery Technologies Recent Advances in the Synthesis of New Antimycobacterial Agents Based on the 1H-1,2,3-Triazoles
Current Topics in Medicinal Chemistry Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Current Drug Targets Near Infrared Optical Technologies to Illuminate the Status of the Neonatal Brain
Current Pediatric Reviews Synthesis and Screening of Substituted Thiosemicarbazone Derivatives: An Approach towards Novel Anticonvulsant Search
Central Nervous System Agents in Medicinal Chemistry Editorial (Thematic Issue: Measurements of ABC Transporters at the Blood-Brain Barrier: Novel Methods and Applications)
Current Pharmaceutical Design Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Review of the Biological Activity of Maslinic Acid
Current Drug Targets Functional Neuroimaging of Sleep Disorders
Current Pharmaceutical Design Clinical Profile of Mortality among Chronic Schizophrenic Patients: A Local Pilot Survey in Iran
Current Psychiatry Research and Reviews Modulation of GABAA Receptors by Natural Products and the Development of Novel Synthetic Ligands for the Benzodiazepine Binding Site
Current Drug Targets Metabolic Syndrome and Psychiatric Practice: Clinical and Management Issues
Current Psychiatry Reviews The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in Schizophrenia
Current Pharmaceutical Design Pharmacological Effects and Chemical Constituents of Bupleurum
Mini-Reviews in Medicinal Chemistry The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets AMPA Receptor Antagonists as Potential Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Synthesis, Antibacterial and Antifungal Activities of 3-Amino-5- methyl[1,1'-biphenyl]-2,4-dicarbonitrile Derivatives
Letters in Drug Design & Discovery Anticonvulsant and Antitubercular Activities of 6-Phenyl/Biphenyl-4-yl-2- [2-(pyridin-2-ylamino)-ethyl]- and 6-(Biphenyl-4yl)-2-(2N-subtituted amin- 1-yl)-ethyl derivatives of 4,5-dihydropyridazin-3(2H)-one
Letters in Drug Design & Discovery Inflammasome and Atherogenesis
Current Pharmaceutical Design